Table 1:

Demographic and Clinical Characteristics of the Lung Disease Subjects That Had Plasma CXCL13 Concentration Assays

	IPF	COPD
N	95	128
Age, yr	69 ± 1 (70, 51–84)	65 ± 1 (66, 47–81)*
Sex, % male	74	50*
FVC % predicted	66 ± 2 (65, 25–126)	88 ± 2 (89, 38–144)*
FEV1 % predicted	78 ± 2 (76, 31–133)	65 ± 2 (67, 12–130)*
FEV1/FVC	0.84 ± 0.01 (0.84, 0.71–1.22)	0.55 + 0.01 (0.59, 0.15–0.83)*
DlCO %predicted	50 ± 2 (49, 14–109)	60 ± 2 (61, 17–122)*
%-910 HU	ND	27.8 + 1.8 (23.4, 0.6–73.3)
Smoking history, %	53	100*

Definitions of abbreviations: %-910 HU = percentages of lung pixel values less than 910 Hounsfield Units; COPD = chronic obstructive pulmonary disease; CXCL13 = C-X-C motif chemokine 13; Dl_CO = diffusing capacity of carbon monoxide; IPF = idiopathic pulmonary fibrosis; ND = not determined.

Data are depicted as means ± SE, and in parenthesis (median, minimum-to-maximum ranges). Smoking history denotes subjects with ≥5 pack-years of cigarette smoking.

^*P ≤ 0.001 for comparisons between the IPF and COPD cohorts.